Trial · NCT00167180
Post Transplant Donor Lymphocyte Infusion
NCT00167180, Phase 2, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2017-07-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post Transplant Donor Lymphocyte Infusion. Trials, record NCT00167180. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00167180
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post Transplant Donor Lymphocyte Infusion
- NCT number
- NCT00167180
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 57 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
- Interventions
- Donor Lymphocyte Infusion, Induction Chemotherapy
- First posted
- 2005-09-14
- Last updated
- 2019-07-30
- Results first posted
- 2017-07-11
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Alive | 1 Year | The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate. Overall survival will be defined as time from date of enrollment to date of death or censored at the date of last documented contact for patients still alive. |
| Secondary | Number of Patients Alive Without Disease | 1 Year | The number of patients alive one year after treatment without any signs or symptoms of the cancer being treated or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works. |
| Secondary | Number of Participants With Complete Remission | one year | In complete remission, all signs and symptoms of cancer that can be detected with modern technology have disappeared, although cancer still may be in the body. |
| Secondary | Number of Patients With Acute Graft-Versus-Host Disease | Day 100 | Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host. |
| Secondary | Number of Patients With Bone Marrow Aplasia | Day 100 | Aplastic anemia is a disorder in which the bone marrow greatly decreases or stops production of blood cells. In aplastic anemia, the basic structure of the marrow becomes abnormal, and those cells responsible for generating blood cells (hematopoietic cells) are greatly decreased in number or absent. These hematopoietic cells are replaced by large quantities of fat. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Alive | 1 Year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients Alive Without Disease | 1 Year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Complete Remission | one year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients With Acute Graft-Versus-Host Disease | Day 100 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients With Bone Marrow Aplasia | Day 100 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Alive | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 3 | Participants | ||
| Number of Patients Alive | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 20 | Participants | ||
| Number of Patients Alive Without Disease | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 2 | Participants | ||
| Number of Patients Alive Without Disease | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 10 | Participants | ||
| Number of Participants With Complete Remission | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 7 | Participants | ||
| Number of Participants With Complete Remission | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 22 | Participants | ||
| Number of Patients With Acute Graft-Versus-Host Disease | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 10 | Participants | ||
| Number of Patients With Acute Graft-Versus-Host Disease | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 10 | Participants | ||
| Number of Patients With Bone Marrow Aplasia | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 0 | Participants | ||
| Number of Patients With Bone Marrow Aplasia | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 1 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chronic Myelogenous Leukemia (CML) | 0 | |
| Overall Study | STARTED | Non-CML or CML Failing Donor Lymphocyte Infusion | 57 | |
| Overall Study | COMPLETED | Chronic Myelogenous Leukemia (CML) | 0 | |
| Overall Study | COMPLETED | Non-CML or CML Failing Donor Lymphocyte Infusion | 57 | |
| Overall Study | NOT COMPLETED | Chronic Myelogenous Leukemia (CML) | 0 | |
| Overall Study | NOT COMPLETED | Non-CML or CML Failing Donor Lymphocyte Infusion | 0 |
Source ClinicalTrials.gov
Adverse events130
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acute Graft vs. Host Disease | General disorders | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 6 | 15 | |
| other | Acute Graft vs. Host Disease | General disorders | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 0 | 42 | |
| other | Acute Renal Failure | Renal and urinary disorders | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 0 | 15 | |
| other | Acute Renal Failure | Renal and urinary disorders | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 1 | 42 | |
| other | Acute Respiratory Distress Syndrome | Respiratory, thoracic and mediastinal disorders | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 0 | 15 | |
| other | Acute Respiratory Distress Syndrome | Respiratory, thoracic and mediastinal disorders | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 1 | 42 | |
| other | Anaphylactic Reaction to Anti-Thymocyte Globulin | Immune system disorders | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 1 | 15 | |
| other | Anaphylactic Reaction to Anti-Thymocyte Globulin | Immune system disorders | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 0 | 42 | |
| other | Atrial Flutter | Cardiac disorders | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 0 | 15 | |
| other | Atrial Flutter | Cardiac disorders | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 1 | 42 |
1 to 10 of 130Source ClinicalTrials.gov
See all 130 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 12 | 15 |
| Total, all-cause mortality | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 22 | 42 |
| Total, other adverse events | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 12 | 15 |
| Total, other adverse events | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 11 | 42 |
| Total, serious adverse events | DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg | 8 | 15 |
| Total, serious adverse events | DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg | 3 | 42 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 17579184 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons7
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients With Acute Graft-Versus-Host Disease | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients Alive Without Disease | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients With Bone Marrow Aplasia | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Participants With Complete Remission | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients Alive | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: deaths from any cause | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00167180
GET https://conductscience.org/api/trials/v1/NCT00167180/events?page=2